Sandoz has announced that it will no longer pursue a generic rival to GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) asthma treatment for the US market.
Sandoz Will Not Pursue US Advair Rival
Discontinuing Development Leads To $442m Impairment
Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.
